Drug Trial Radar · NCT05648448
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Feb 22, 2023
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator
Conditions
- Influenza
- Influenza, Human
Interventions
OseltamivirDrug
Oral oseltamivir 75mg BD for 5/7
FavipiravirDrug
Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
ZanamivirDrug
Inhaled zanamivir 10mg BD for 5/7
BaloxavirDrug
Oral baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0
MolnupiravirDrug
Oral molnupiravir 800mg BD for 5/7
PeramivirDrug
Intravenous peramivir 600mg once only
LaninamivirDrug
Inhaled laninamivir 40mg once only
Oseltamivir and BaloxavirDrug
Oseltamivir 75mg BD for 5/7 and Baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0
Oseltamivir and FavipiravirDrug
Oseltamivir 75mg BD for 5/7 and favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
Favipiravir and BaloxavirDrug
favipiravir 1800mg BD D0 and 800mg BD for a further 4/7 Baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of viral clearance for currently available drugs and those with potential activityTime frame: Days 0 - 5
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Universidade Federal de Minas Gerais
Minas Gerais, Brazil · Recruiting
Laos-Oxford-Mahosot Wellcome Trust Research unit
Vientiane, Laos · Recruiting
Sukraraj Tropical & Infectious Disease Hospital
Kathmandu, Nepal · Recruiting
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.